MedVi vs CoreAgeRx: Pricing, meds, and process compared
MedVi vs CoreAgeRx is a price and product battle: MedVi advertises compounded semaglutide starting at $179 for the first month with no clinic visits and 24/7 certified medical support, while CoreAgeRx advertises flat monthly pricing with semaglutide or tirzepatide options and no membership fees. Early verdict: choose MedVi if you want a low promotional entry price and continuous 24/7 clinician support; choose CoreAgeRx if you prefer predictable flat monthly pricing and access to tirzepatide as well as semaglutide.
Start MedVi: See $179 First-Month Offer
How MedVi and CoreAgeRx differ at a glance
Both platforms are telehealth-first and direct-pay. The comparison below focuses on the most distinctive differences supported in the source material: pricing structure, medication options, visit model and process, compounded medication status and published support or guarantees.
| Criteria | MedVi | CoreAgeRx |
|---|---|---|
| Starting price | Winter promo starting at $179 for first month | $79/mo for semaglutide; $129/mo for tirzepatide listed as same price every month |
| Ongoing pricing | Standalone month $299; three-month plan $649 (about $216/mo) | Flat monthly pricing advertised: “Same Price. Every Month.” No membership fees |
| Medication options | Clinically dosed compounded semaglutide only | Semaglutide up to 1.0 mg or tirzepatide up to 7.5 mg options listed |
| Visit / process | Simple online intake, no clinic visits; clinician review after checkout | 3-minute online visit; clinician-reviewed online treatment |
| Support and claims | 24/7 support from certified medical professionals; patient-reported outcomes cited | Advertising cites consistent pricing and customer results but captured landing details were limited |
Pricing structure: promo entry versus flat monthly rates
MedVi leans on a promotional first-month price: the landing-page evidence shows a winter promo at $179 for the first month including fast, free shipping. The source makes clear the ongoing standalone month rises to $299 and offers a three-month plan at $649. CoreAgeRx is presented as a flat pricing model: the captured evidence repeats “Same Price. Every Month.” with semaglutide at $79 per month and tirzepatide at $129 per month and states no membership fee and no price hikes. These are contrasting approaches: MedVi explicitly warns the ongoing price is substantially higher than the first-month promo, while CoreAgeRx emphasizes predictable monthly billing.
Explore CoreAgeRx Flat Pricing
Medication options and compounded status
MedVi advertises clinically dosed compounded semaglutide and repeatedly notes that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. CoreAgeRx lists both semaglutide and tirzepatide dosing options on the captured materials and highlights that treatment is clinician-determined. The sources support this distinction: MedVi focuses on compounded semaglutide only, while CoreAgeRx explicitly lists tirzepatide availability up to 7.5 mg as well as semaglutide up to 1.0 mg.
If access to tirzepatide is important, the source evidence points to CoreAgeRx; if a compounded semaglutide program and 24/7 support are priorities, the source evidence favors MedVi.
Process, clinician review and support
MedVi’s process is described as a simple online intake with no clinic visits and an OpenLoop Health clinician review after checkout. MedVi emphasizes 24/7 support from certified medical professionals. CoreAgeRx captures a “3-minute online visit” and clinician-reviewed online treatment, with an emphasis on no membership fees and consistent monthly billing. Both require a clinician to determine medical appropriateness, according to the supplied evidence.
Check MedVi Process and 24/7 Support
Regulatory notes, published results, and limitations
Both sources include regulatory or cautionary language. MedVi explicitly states compounded GLP-1s are produced in FDA-regulated facilities but are not FDA-approved. It also notes results vary and that patient-reported outcomes were used. CoreAgeRx captured content also notes medication-specific approval status must be confirmed and warns branded and compounded products are not interchangeable. Neither source provides an FDA approval claim for compounded products in the captured materials.
Near-conclusion comparison
MedVi vs CoreAgeRx contrasts a promotional entry with ongoing higher MedVi pricing and 24/7 support against CoreAgeRx’s flat monthly pricing and broader medication options including tirzepatide. The primary keyword MedVi vs CoreAgeRx has been addressed above and the differences are supported by the supplied source material.
See CoreAgeRx Medication Options
Choose based on what matters to you
Choose MedVi if you want a low promotional first month, a fully online intake with no clinic visits, clinically dosed compounded semaglutide, and 24/7 certified medical support as described in the source material. Choose CoreAgeRx if you prefer predictable flat monthly pricing with no membership fees and want access to either semaglutide or tirzepatide dosing options per the captured evidence.